- Home
- ETON vs NMRA Comparison
ETON vs NMRA Comparison
Compare ETON & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETON | NMRA |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 689.8M | 554.0M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ETON | NMRA |
|---|---|---|
| Price | $30.29 | $1.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $39.33 | $7.50 |
| AVG Volume (30 Days) | 343.5K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $40.90 | N/A |
| Revenue Next Year | $47.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $13.09 | $0.66 |
| 52 Week High | $32.31 | $3.65 |
Technical Indicators
Market Signals| Indicator | ETON | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.74 | 35.91 |
| Support Level | $16.17 | $1.81 |
| Resistance Level | $32.31 | $1.90 |
| Average True Range (ATR) | 1.54 | 0.21 |
| MACD | 0.26 | -0.04 |
| Stochastic Oscillator | 79.33 | 8.11 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.